Compare Illumina, Inc. (ILMN) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MPLX LP — how do they compare? Illumina, Inc. trades at $278 (market cap $39.95B), while MPLX LP trades at $56.35 (market cap $58.11B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays a 7.51% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MPLX | |
|---|---|---|
Market Cap | $39.95B | $58.11B |
Volume | 3,169,503 | 687,483 |
Sector | Health | Energy |
52-Week High | $293.69 | $60.51 |
52-Week Low | $91.00 | $47.80 |
Typical Hold Time | 83 Days | — |
Enterprise Value | $41.31B | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
MPLX trades at $56.12, down 1.63% with a bearish technical signal. The stock shows strong fundamentals with a 12.33 P/E ratio, 40.45% net income margin, and consistent dividend payments. Recent earnings show mixed results with Q4 2025 beating expectations but subsequent quarters missing targets. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 13.7% upside potential from current levels.
The outlook remains positive given MPLX's resilient midstream business model with fee-based revenues insulating it from energy price volatility. Key risks include potential energy market downturns and execution challenges in the Permian Basin expansion. The company's strong cash flow generation supports its 8% dividend yield, making it attractive for income investors seeking energy exposure with reduced commodity price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
